Baker Bros. Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Baker Bros. Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.2M	Buy	+445,975	New	+$42M	0.24%	39
2025 Q1	–	Sell	-190,476	Closed	-$7.88M	–	94
2024 Q4	$7.88M	Hold	190,476	–	–	0.08%	59
2024 Q3	$7.43M	Hold	190,476	–	–	0.08%	61
2024 Q2	$6.51M	Hold	190,476	–	–	0.08%	56
2024 Q1	$4.78M	Hold	190,476	–	–	0.06%	63
2023 Q4	$5.62M	Hold	190,476	–	–	0.06%	61
2023 Q3	$6.02M	Buy	+190,476	New	+$5.22M	0.03%	62
2021 Q4	–	Sell	-647,313	Closed	-$12.9M	–	123
2021 Q3	$12.9M	Hold	647,313	–	–	0.06%	70
2021 Q2	$11.2M	Hold	647,313	–	–	0.05%	73
2021 Q1	$12.8M	Hold	647,313	–	–	0.06%	70
2020 Q4	$11.3M	Buy	647,313 +94,304	+17%	+$1.85M	0.04%	71
2020 Q3	$10.7M	Sell	553,009 -30,324	-5%	-$651K	0.04%	64
2020 Q2	$11.4M	Hold	583,333	–	–	0.05%	56
2020 Q1	$8.17M	Buy	583,333 +250,000	+75%	+$4.1M	0.05%	52
2019 Q4	$8.17M	Hold	333,333	–	–	0.04%	59
2019 Q3	$3.35M	Buy	+333,333	New	+$4.09M	0.02%	73

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Baker Bros. Advisors's MIRM Position: Q1 2026 in Review

Baker Bros. Advisors opened a new position in Mirum Pharmaceuticals (MIRM) in Q1 2026: 445,975 shares worth $41.2M. The stake represents 0.24% of the portfolio and ranks #39 among its holdings. This is a return to the name: Baker Bros. Advisors previously reported a position in MIRM as recently as Q4 2024.

Baker Bros. Advisors first reported a position in MIRM in Q3 2019 and has held it in 16 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Baker Bros. Advisors held 445,975 shares of Mirum Pharmaceuticals worth $41.2M as of Q1 2026.
Mirum Pharmaceuticals was a new Baker Bros. Advisors position in Q1 2026.
Mirum Pharmaceuticals made up 0.24% of Baker Bros. Advisors's portfolio in Q1 2026, its #39 holding.
Baker Bros. Advisors first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 16 quarters since.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.